Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have received an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.00.
Several research firms have issued reports on CDXS. Stephens restated an “overweight” rating and set a $5.00 price objective on shares of Codexis in a report on Monday. Wall Street Zen raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Saturday. Benchmark restated a “hold” rating on shares of Codexis in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Finally, Piper Sandler reduced their price target on shares of Codexis from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, August 17th.
Check Out Our Latest Research Report on Codexis
Institutional Trading of Codexis
A number of hedge funds have recently modified their holdings of CDXS. Bank of New York Mellon Corp raised its stake in shares of Codexis by 2.4% during the 1st quarter. Bank of New York Mellon Corp now owns 209,645 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 4,896 shares in the last quarter. Post Resch Tallon Group Inc. lifted its holdings in shares of Codexis by 1.9% during the 3rd quarter. Post Resch Tallon Group Inc. now owns 573,953 shares of the biotechnology company’s stock valued at $798,000 after buying an additional 10,475 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Codexis during the 2nd quarter valued at about $35,000. Corient Private Wealth LP bought a new stake in shares of Codexis in the 2nd quarter valued at approximately $37,000. Finally, Simplicity Wealth LLC bought a new stake in shares of Codexis in the 2nd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.
Codexis Price Performance
Shares of CDXS traded down $0.02 during trading hours on Monday, hitting $1.14. 139,915 shares of the company were exchanged, compared to its average volume of 1,387,668. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.06 and a quick ratio of 2.99. The company has a market capitalization of $124.84 million, a PE ratio of -5.70 and a beta of 2.38. The firm has a fifty day simple moving average of $1.29 and a 200-day simple moving average of $1.78. Codexis has a one year low of $0.90 and a one year high of $2.98.
Codexis (NASDAQ:CDXS – Get Free Report) last announced its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. Codexis had a negative return on equity of 45.54% and a negative net margin of 21.77%. The company had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.72 million. As a group, sell-side analysts predict that Codexis will post -0.37 earnings per share for the current year.
Codexis Company Profile
Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.
Featured Stories
- Five stocks we like better than Codexis
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.
